16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest treatment with cilnidipine or inhibiting DNM1L could help treat MI. Screening of antihypertensive drugs in primary rat cardiac fibroblasts cultured under hypoxic conditions identified that...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Horizant gabapentin enacarbil: Phase II started

XenoPort said NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA) began the double-blind, placebo-controlled, U.S. Phase II NCIG-006 trial to evaluate 600 mg oral Horizant twice daily for 26 weeks in about 350 patients....
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Horizant gabapentin enacarbil update

XenoPort and the Willis-Ekbom Disease (WED) Foundation began the Patient Odyssey survey in patients with RLS to evaluate challenges of long-term disease management, quality of life, emotional burden associated with RLS and impact on relationships...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Calcium channel N-type; calcium channel P/Q-type Cell-based and mouse studies identified an agonist of N- and P/Q-type calcium channels that could help...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Collapsin response mediator protein-2 (DPYSL2; CRMP-2); calcium channel N-type Mouse studies suggest blocking interactions between CRMP-2 and the N-type calcium...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

Horizant gabapentin enacarbil: Phase IIb data

Top-line data from a 30-week, double-blind, dose-ranging, North American Phase IIb trial in 526 patients showed that gabapentin enacarbil missed the primary endpoint of significantly reducing the number of migraine headache days during the last...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Clinical News

XP13512: Phase II data

Top-line data from a double-blind, crossover Phase II trial in 96 evaluable patients showed that 3,600 mg/day Solzira met the primary endpoint of significantly reducing 24-hour average pain intensity score from baseline to the end...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Clinical News

Solzira: Phase IIb data

Top-line data from a 14-week, double-blind Phase IIb trial in 376 PHN patients showed that 1,200, 2,400 and 3,600 mg/day Solzira met the primary endpoint of significantly reducing the 24-hour average pain intensity score from...